T HERE is a growing consensus that routine screening for prostate cancer with prostate -specifi c antigen (PSA) results in the diagnosis and treatment of prostate cancer in men who otherwise would not have been diagnosed during their lives ( 1 -12 ). What is less clear is whether routine PSA screening has any benefi t -whether it results in fewer deaths from prostate cancer. Prostate cancer differs from most other cancers in that, with the exception of metastatic disease, stage at diagnosis has a small impact on overall survival ( 13 ). The two large randomized prospective trials of PSA screening have produced confl icting results ( 14 -17 ). A study of 76,693 men aged 55 -74 in the United States found no decrease in prostate cancer mortality in men who received annual testing compared with usual care in 10 and 13 years of follow-up ( 14 , 15 ). However, the usual care group had high rates of PSA testing. In contrast, a European Study of 162,243 men aged 50 -74 found a 19% decrease in prostate cancer mortality in 9 years of follow -up and a 29% reduction after 11 years follow -up ( 16 , 17 ). This translated to one prostate cancer death prevented for each 1,410 men screened at 9 years and one less death per 1 , 055 men at 11 years. This study also found a high risk of overdiagnosis, with 48 additional men diagnosed and treated for prostate cancer for each prostate cancer death prevented.
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In addition to prospective trials, a number of investigators have explored the impact of the PSA testing through ecological analyses, comparing the rates of PSA testing in different geographic areas to rates of prostate cancer diagnoses and mortality ( 5 , 18 -20 ) . Most fi nd greater incidence and treatment of prostate cancer in the high PSA testing area but no differences in prostate cancer mortality.
In this study , we take advantage of the fact that PSA screening rates vary considerably from one area of the country to another, and ask whether differences in rates of PSA testing across U . S . counties are associated with differences in the rate of men treated for prostate cancer and also deaths from prostate cancer. We hypothesized that the fi ndings from this analysis would be similar to those of the prospective trial of PSA testing in Europe ( 16 , 17 ) because the ecological analysis of U . S . data avoids the issue of the high underlying rate of PSA testing that complicated the U . S . trial of PSA testing ( 14 , 15 ) .
M ethods
We selected cohorts of male Medicare beneficiaries 66 -74 years of age from the nationally representative 5% Medicare sample who had complete enrollment in parts A and B and no h ealth m aintenance o rganization (HMO) enrollment in the year prior to and the year of selection for inclusion in the study. Men with claims consistent with a prior diagnosis of or treatment for prostate cancer in the preceding 12 months were excluded.
Our main analysis compared the association of the PSA testing rate in men aged 66 -74 in 1997 in each county with the rate of prostate biopsies and new prostate cancer treatments in 1997 in those counties as well as lagged age-group -specifi c mortality rates for prostate cancer and nonprostate cancer from 1998 to 2007.
Mortality data were drawn from the National Vital Statistics System ' s bridged-race fi les. Population denominators for each county were derived from the 5% Medicare sample denominator fi le, including all male benefi ciaries regardless of HMO status or enrollment in p arts A and B. Lagged age -group -specifi c mortality rates were calculated for prostate cancer mortality (The International Statistical Classification of Diseases and Related Health Problems [ICD]-9 C ode 185 and ICD-10 C ode C61) and nonprostate cancer mortality (all other deaths). In lagging the rates, we generated numerators and denominators that were shifted 1 year for each year out from PSA testing.
Rates were calculated at the county level for PSA testing (Current Procedural Terminology codes 84152 -84154), prostate biopsy (Current Procedural Terminology codes 55700 -55705), and prostate cancer treatment, which included parenteral gonadotropin -releasing hormone (GnRH) agonists (Healthcare Common Procedure Coding System codes J9202, J1950, J9217, J9218, J9219, and J3315), orchiectomy (Current Procedural Terminology codes 54520 -54522 and 54530 -54535), prostatectomy (Current Procedural Terminology codes 55810 -55845 and ICD-9 procedure 60.5), or radiation therapy (Healthcare Common Procedure Coding System codes 77401 -77499, 77520, 77523, 77750 -77799, G0256, G0261 and ICD-9 procedures 92. 21 -92.29) .
The Area Resource File includes percent of county living in poverty, percent of county that was b lack, percent uninsured , and housing density. County HMO market penetration was calculated as the number of male benefi ciaries aged 66 and older who had one or more months of HMO coverage divided by the total number of male benefi ciaries aged 66 and older. Latitude was obtained from the U . S . Census Bureau and is dichotomized to above and below the 40th parallel in the analyses ( 21 ) .
We performed linear regression models to examine the association of PSA testing in 1997 with biopsies, treatments , and mortality. These models were weighted by the number of men in each county in the relevant group. In each model , we controlled for age group (66 -69 and 70 -74), percent poverty, percent b lack, percent uninsured, housing density , and HMO market penetration. For these analyses , we only included the 1 , 067 counties with 50 or more men aged 66 -74 with parts A and B and no HMO in the 5% Medicare sample. This equated to more than 1 , 000 men in that age group in each county .
We also performed analyses stratifi ed by age (66 -69 and 70 -74) and race (black and white). In supplemental analyses , we repeated the main analyses without restricting the county size to 50+ benefi ciaries in the 5% sample and instead included all 3 , 120 linkable U . S . counties. In another analysis , we examined the cross-sectional association between PSA testing in 2007 with mortality in 2007. We also examined the association of PSA testing in men aged 65 -74 in 1997 with age-standardized mortality from prostate cancer for men aged 65 -74 or 70 -79 years from 1998 to 2007. We generated age-standardized mortality rates using the direct method and the U . S . 2000 standard million for 1998 -2007 ( 22 ) . We next looked at the rate of men who received PSA testing in either 1997 or 1998 and its association with agelagged mortality from 1999 to 2007. We also compared PSA testing in 1997 with a standardized prostate cancer mortality ratio compiled across 1998 -2007 ( 23 ) . This ratio compared the prostate cancer mortality rates at the county level with the rate for the entire United States . We also used a zero -infl ated Poisson regression model to look at the association between PSA testing and counts of prostate cancer deaths from 1998 to 2007. In addition, we present data from the United States and European prospective trials of PSA testing for comparison ( 14 -17 ) . We used STATA version 11 (Stata C orp, College Station, TX) for all analyses. Figure 1 presents the cumulative distribution of rates of PSA testing in the 1 , 067 U.S. counties with at least 1 , 000 men aged 66 -74 with p arts A and B Medicare (allowing for at least 50 analyzable men in the 5% sample). In 1997, 10% of men lived in counties where 26% or fewer men received PSA testing and 10% lived in counties where 50% or greater received testing. Table 1 presents similar cumulative distributions of the rates of men receiving prostate biopsies, treatment for prostate cancer , and deaths from prostate cancer. There was substantial variation among counties in all measures.
R esults
We assessed the stability of county-level PSA testing rates by comparing the rates of PSA testing in 1997 to the rates 1 year and 11 years later, in 1998 and 2007. We ranked counties by PSA testing rate in each year and then categorized the ranking into quintiles. Of the counties in the top quintile in PSA testing in 1997, 73% were in the fi rst or second quintile in 1998 and 59% in 2008. Of the counties in the lowest ( fi fth ) quintile in 1997, 75% were in the fourth or fi fth quintile in 1998 and 67% in 2008 (all p < .001). Table 2 presents the results of regression models examining the association of county PSA testing rates in men aged 66 -74 with the rate of prostate cancer biopsies and new prostate cancer treatments in 1997 and with prostate cancer mortality and mortality from all other causes from 1998 through 2007. These multivariable models controlled for percent poverty, percent b lack, percent uninsured, housing density, and HMO penetration in each county. PSA testing rates are significantly associated with biopsy rates, treatment rates, and prostate cancer mortality (all p < .001) but not with nonprostate cancer mortality ( p = .60). For every 100,000 men screened in 1997, there were 4 , 894 additional men undergoing prostate biopsies and 1 , 597 additional men undergoing treatment for prostate cancer in 1997. There were also 61 fewer deaths from prostate cancer in 1998 -2007 for every 100,000 men receiving PSA testing in 1997. Of the 1 , 597 additional men receiving treatment for prostate cancer, 1 , 138 received parenteral GnRH agonists, 222 underwent prostatectomy, and 778 received radiation treatment.
We also asked how much of the variation among U . S . counties in mortality from prostate cancer was explained by the variation in rates of PSA testing and also by variations among counties in all the variables included in Table 2 . This is expressed by the square of the correlation coefficient, or R 2 , in Table 2 . The variation among counties in all the variables included in Table 1 explained 55% of the variation in prostate cancer mortality. However, variation in the PSA testing rate by itself explained less than 0.2% of the variation in prostate cancer mortality. Table 3 presents the results of analyses similar to those presented in Table 2 , with the population stratifi ed by age and race. The number of counties included in each analysis varies because of the requirement for 50+ men per county in the 5% Medicare sample with the relevant characteristic. The number of b lack men receiving treatment per 100,000 b lack men undergoing PSA testing was signifi cantly higher than in white men. There were also trends for more biopsies and fewer prostate cancer deaths in b lack men, but these differences were not signifi cant, perhaps due to the small number of observations (120 counties) included in the analysis for b lack men. There were also higher treatment rates associated with PSA testing in men aged 70 -74 than in those 66 -69, but this difference did not reach statistical signifi cance ( p = .06).
We also performed supplemental analyses estimating the association between PSA testing and treatment and mortality from prostate cancer to examine the robustness of the results shown in Table 2 (results not shown). One model included all U . S . counties in the analysis -not just those with 50 or more men in the appropriate age range in the 5% Medicare sample. In another analysis, we used the rate of men receiving PSA testing in either 1997 or 1998 rather than the 1997 rate. We also looked at the cross-sectional relationship of PSA testing and prostate cancer mortality in the same year. In addition, we used standardized mortality ratios for prostate cancer rather than rates in some analyses. Finally, we used a zero -inflated Poisson regression of PSA testing in 1997 with the number of prostate cancer deaths in 1998 -2007.
All of the different analyses found a signifi cant association of PSA testing rates with both new prostate cancer treatments and mortality from prostate cancer. The range of estimates of additional men treated for prostate cancer per 100,000 men receiving PSA testing was 1 , 597 -2 , 714, and the range for prostate cancer deaths avoided was 22 -104. These estimates are similar to the results of the European trial of PSA testing published in 2012: 2 , 799 additional cancer cases treated (/100,000) and 107 deaths (/100,000) prevented. This is in contrast to the U . S . trial which found 901 additional men treated for prostate cancer (/100,000) and a nonsignifi cant increase of 34 additional prostate cancer deaths (/100,000) associated with PSA testing.
D iscussion
There has been a growing consensus that the introduction of PSA testing has contributed to some decreases in prostate cancer mortality but at a cost of greater numbers of men diagnosed with and treated for prostate cancer ( 1 , 9 -11 ). This has led to a reexamination of recommendations on PSA screening. For example, the American Cancer Society in 2010 changed from a recommendation of yearly PSA screening for men aged 50 and older to one emphasizing individual decision making based on the patients ' individual risks and their values ( 24 ) . In 2011, the U.S. Preventive Services Task Force signaled its intention to change its guideline on prostate cancer screening to recommending against routine PSA testing in asymptomatic men at normal risk, regardless of age. This has generated objections from various quarters ( 25 , 26 ) . Because of this controversy, it becomes important to furnish patients and their physicians with accurate data on which to base discussions about PSA screening. Typically, the most valid information comes from prospective trials. However, the two large prospective trials published in 2009 and with extended follow-up published in 2012 produced confl icting results ( 14 -17 ) and appeared to have minimal impact on PSA screening in the community ( 27 ) . PSA screening is highly prevalent, even among men aged 80 and older, where no organization has ever recommended testing ( 28 ) . In addition to their contradictory results, other aspects of the two large trials may limit generalizability of their results. A major limitation of the American trial was the high PSA testing rate in the control group ( 14 , 15 ) . In addition, the benefi t of screening in the European trial was restricted to participant s aged 55 -69 years old ( 16 , 17 ) . It is possible, however, that there was an insuffi cient number of men older than 69 enrolled to detect potential benefi t in the European study. Our study examined benefi ciaries aged 66 -75 years old, somewhat older than those studied by either trial. We found that an increase of PSA testing at the county level was associated with an increase in diagnosis and treatment of prostate cancer and a decrease in prostate cancer mortality. As a control, we also examined mortality from all causes other than prostate cancer and found no association with PSA testing. This fi nding suggests that the association of PSA testing and lower prostate cancer mortality is specifi c; that is, PSA testing was not a marker for better overall health or better access to and receipt of health care.
PSA testing appeared to have a bigger impact on black patients, with more men biopsied and treated for prostate cancer and more deaths from prostate cancer prevented. However, only the difference in men treated for prostate cancer was statistically signifi cant, and the analyses of black men were limited to the 120 counties with 50 or more Table 2 . Linear R egression M odels E stimating the N umber of A dditional M en W ho U ndergo P rostate B iopsies or P rostate C ancer T reatment and the R eduction in D eaths from P rostate C ancer, P er 100,000 M en W ho R eceive PSA T esting * relevant black patients in the 5% sample, so the results might not generalize to counties with lower densities of older black residents. Most of the excess treatment for prostate cancer associated with increasing PSA rates was due to men receiving GnRH agonists and/or radiation. Though there is no evidence to support the practice, it became very common in the 1990s for older men with low -grade prostate cancer to receive GnRH agonists ( 29 , 30 ) . Indeed, some physicians were administering GnRH agonists to older men with elevated PSA levels even without a biopsy-proven diagnosis of prostate cancer ( 31 ) . This is concerning, given the substantial late toxicities associated with GnRH agonist use ( 32 , 33 ) .
The interpretation of our analyses rests on several assumptions. First, we are assuming that the variation in PSA testing rates is driving the variation in prostate cancer treatments and mortality. An alternative explanation is that some unmeasured factor that varies among counties might be responsible for both PSA screening and prostate cancer diagnoses and mortality. This is a limitation of all ecological analyses and cannot be directly refuted. On the other hand, it is diffi cult to envision what this unmeasured variable would be. The factor would have to be specifi c for prostate cancer mortality, not overall mortality. Also, the known risk factors for prostate cancer mortality would tend to be associated with higher PSA testing rates, not lower, and we controlled for the most obvious risk factors for prostate cancer mortality such as age, racial composition , and measures of socioeconomic status.
Another assumption in our ecological analyses is that populations and PSA testing rates within counties are stable over time. We found that counties with high or low rates in 1997 tended to maintain those high and low rates up to 11 years later. We assume that the association of prostate cancer mortality in 1998 -2007 with PSA testing rates in 1997 was driven by the fact that the 1997 rates were generally refl ective of the rates in prior and subsequent years. We explored a number of alternative analyses, all ecological, in order to test the robustness of the results. All of these alternative analyses found signifi cant associations between PSA testing and new treatments and between PSA testing and prostate cancer mortality. Most of the point estimates produced by these analyses were close to those produced by the main analysis and also to the results of the European study.
There are several limitations to this study. First, our measure of mortality from prostate cancer is derived from vital statistics. Studies comparing prostate cancer deaths in vital statistics data to medical record review have found more than 90% agreement ( 34 -36 ) and no effect of different levels of PSA testing on coding of prostate cancer deaths ( 35 ) . Another limitation is Medicare data provide no information on stage of cancer at diagnosis or level of PSA. In addition, we limited our sample to benefi ciaries who were enrolled in Medicare parts A and B and who had not been enrolled in an HMO. The results may not be applicable to younger men. Not all PSA testing is for screening. We eliminated men with a diagnosis on any medical claim in the prior year suggestive of a history of prostate cancer before we calculated the rate of PSA testing. Any residual PSA testing for surveillance should have only a minor impact on the estimates of PSA screening rates by county.
In conclusion, our results show that although PSA testing at the county level is associated with modest reductions in mortality from prostate cancer, it is also associated with large increases in the number of men diagnosed and treated for prostate cancer. This supports the generalizability of the results from the European trial of PSA testing and should lead to a more selective use of the PSA test in the future. 
